ANTI-CD137 ANTIGEN-BINDING MOLECULE FOR USE IN CANCER TREATMENT

• Main Authors: HAMADA Koki, UCHIKAWA Ryo, TANIGUCHI Kenji, NARITA Yoshinori, MIKAMI Hirofumi, SAKURAI Mika, HORIKAWA Sayuri, ONO Natsuki
• Format: Patent
• Language: English; Spanish
• Published: 05.09.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

[Problem] The purpose of the present disclosure is to provide: an anti-cancer agent having immune cell activation action, cytotoxic activity, or anti-tumor activity, and yet having little activity against non-tumor tissues such as normal tissues, and also having few side effects; a combination therapy that uses said anti-cancer agent together with other anti-cancer agents; and a pharmaceutical composition for use in the combination therapy. [Solution] Provided are: an anti-cancer agent; a combination therapy using the anti-cancer agent together with other anti-cancer agents; and a pharmaceutical composition for use in the combination therapy. This anti-cancer agent includes an anti-CD137 antigen-binding molecule according to the present disclosure as an active ingredient, where the binding activity of the molecule against CD137 varies depending on a variety of substances (e.g., low molecular compounds) on target tissues. As a result, the anti-cancer agent has immune cell activation action, cytotoxic activity, or anti-tumor activity, and yet has little activity against non-tumor tissues such as normal tissues, and also has few side effects. The anti-cancer agent is expected to be applicable to various types of cancer. El propósito de la presente descripción es proporcionar: agentes anticancerígenos que tienen un efecto activador de la célula inmunitaria, una actividad citotóxica o una actividad antineoplásica, pero que tienen poco efecto en los tejidos no tumorales, tales como tejidos normales, y que tienen pocos efectos secundarios; tratamientos combinados que usan esos agentes anticancerígenos y otros agentes anticancerígenos; y combinaciones farmacéuticas para usar en esos tratamientos combinados. Se proporcionan agentes anticancerígenos que se espera aplicar a varios tipos de cánceres, que tienen un efecto activador de las células inmunitarias, una actividad citotóxica o una actividad antineoplásica, mientras que tienen poco efecto en los tejidos no tumorales, tales como tejidos normales, y que tienen pocos efectos secundarios y usan como un ingrediente activo una molécula de unión al antígeno anti-CD137 de la presente descripción, cuya actividad de unión a CD137 cambia dependiendo de varias sustancias (por ejemplo, compuestos de bajo peso molecular) en tejidos objetivo. También se proporcionan tratamientos combinados que usan los agentes anticancerígenos y otros agentes anticancerígenos, y las composiciones farmacéuticas para usar en esos tratamientos combinados.